Trials / Completed
CompletedNCT00928174
Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Queen's Medical Center · Academic / Other
- Sex
- Male
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether positron emission tomography / computed tomography (PET/CT) using fluorine-18 fluorocholine as an imaging agent can characterize regional responses to anti-androgen therapies in a manner that in the future aid in the customized planning of treatments for patients with androgen-insensitive prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IV administration of fluorine-18 fluorocholine followed by PET/CT imaging | Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy. |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2009-06-25
- Last updated
- 2015-11-11
- Results posted
- 2014-11-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00928174. Inclusion in this directory is not an endorsement.